Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IBI362 (Mazdutide) in Chinese Obese Adolescents
NCT06536023Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mazdutide in obesity (3 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of adverse events and serious adverse events at 20 weeks. Started Aug 2024; status: completed.
02
Drugs
mazdutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06536023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536023.